Analysis of the marketing of rare disease drugs in China based on the First Batch of Rare Disease Catalog
- VernacularTitle:基于《第一批罕见病目录》的我国罕见病药物上市情况分析
- Author:
Feifei PENG
1
;
Junhao JIANG
1
;
Yujian BAO
1
;
Hang ZHENG
1
Author Information
1. School of Pharmaceutical Sciences，Chongqing Medical University，Chongqing 400016，China
- Publication Type:Journal Article
- Keywords:
rare disease;
rare disease drugs;
the first batch of rare disease catalog;
marketing;
trend
- From:
China Pharmacy
2024;35(11):1291-1295
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the marketing status， general characteristics， and time trends of rare disease drugs in China. METHODS Based on 121 kinds of rare diseases included in the First Batch of Rare Disease Catalog， the names and marketing approval information of corresponding drugs with indications were obtained from the databases of the Center for Drug Evaluation， National Medical Products Administration and Yaozhi.com， and the relevant characteristic variables were extracted for descriptive statistical analysis. RESULTS As of December 31， 2022， only 32 of 121 rare diseases have therapeutic drugs available for treatment on the market in China， and 79 rare disease drugs have been approved. Among them， 46.84% of the drugs are domestic drugs， 88.61% of the drugs are approved for use in both adults and children； 67.09% are chemicals and 59.49% are injections. According to the ATC classification， Category A （digestive system drugs） is the most， accounting for 20.25%. The number of rare disease drugs on the market each year is the highest in 2021， with an overall upward trend from 2018 to 2021 and a downward trend in 2022. Among rare disease drugs on the market each year， according to the ATC classification， the number of Category L （antineoplastics and immune inhibitors） will be the largest in 2021， being 5. By dosage form， oral medicines were marketed in the largest number in 2022， and injectable medicines in 2021. CONCLUSIONS In recent years， the number of approved rare disease drugs in China has been continuously increasing， but it is still far from meeting the needs of patients， and there is still a lack of domestically approved rare disease drugs. We should further accelerate the research and development of rare disease drugs， and promote the import and replication of rare disease drugs.
